Literature DB >> 27791201

Optimization of radiotherapy for neck carcinoma metastasis from unknown primary sites: a meta-analysis.

Xiaomei Liu1, Dianhe Li1, Na Li1, Xiaoxia Zhu1.   

Abstract

This meta-analysis was designed to evaluate radiotherapy (RT) options preferable for neck cancer metastases from unknown primary sites (NCUP). Relevant articles published up through September 2015 were selected from EMBASE, Cochrane, PubMed and Web of Science. Thirty-three articles were identified, and relative risks (RRs) and 95% CIs for all pre-specified endpoints were calculated. Surgery plus RT showed an advantage for 5-year overall survival (OS) (RR 0.66, 95% CI 0.52-0.83, p = 0.0004) and neck recurrence (NR) (RR = 0.74, 95% CI 0.59-0.92, p = 0.008) compared to RT alone. The RRs for NR, primary tumor emergence (PTE), and 5-year disease free survival (DFS) for bilateral neck compared to ipsilateral neck irradiation were 0.61 (95% CI 0.41-0.91, p = 0.01), 0.44(95% CI 0.26-0.77, p = 0.004), and 0.81 (95% CI 0.64-1.03, p = 0.09), respectively. Irradiation of the neck plus potential primary tumor sites (PPTS) showed a benefit for 5-year DFS (RR 0.75, 95% CI 0.61-0.92, p = 0.005), NR (RR = 0.72, 95% CI 0.56-0.92, p = 0.009), and PTE (RR = 0.23, 95% CI 0.12-0.45, p < 0.0001) compared to neck-only irradiation. Adverse events occurred more frequently with bilateral neck plus PPTS irradiation. For NCUP, surgery plus RT of the bilateral neck and PPTS was associated with greater improvement of clinical outcomes.

Entities:  

Keywords:  NCUP; meta-analysis; neck carcinoma metastasis; radiotherapy; unknown primary

Mesh:

Year:  2016        PMID: 27791201      PMCID: PMC5346673          DOI: 10.18632/oncotarget.12852

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


INTRODUCTION

Neck cancer metastasis with an unknown primary site (NCUP) presents in patients with neck lymph node involvement in the absence of an identifiable primary tumor [1-3]. The histopathology of NCUP consists of squamous cell carcinoma, adenocarcinoma, and other undifferentiated carcinomas [1-3]. The often-extensive diagnostic workup to identify the primary site can include physical examination, chest X-ray, endoscopy, biopsy, computed tomography (CT) or magnetic resonance imaging (MRI), and positron emission tomography (PET). Nonetheless, in approximately 2% to10 % of NCUP cases the primary site remains unidentified [1-12]. NCUP is thought to be potentially curable [2], but the data addressing the therapeutic protocols and outcomes of NCUP treatment are limited and controversial. The proposed treatment modalities include surgery alone, radiotherapy (RT) alone, and a combination of RT and surgery. Opinions on the field design for RT also vary. Some investigators have recommended involved-field irradiation, such as ipsilateral neck irradiation only [7, 11–14], while others suggest extended field irradiation, including prophylactic irradiation of potential head and neck mucosal sites and both sides of the neck [1, 4, 6, 15]. Differences in treatment strategy and patient selection have led to inconsistent results. Consequently, the reported 5-year overall survival (OS) rates for patients with NCUP range from 16% to 86%, and the local control rates range from 37% to 91%. The present meta-analysis was performed in an effort to identify the optimal treatment regimen for NCUP, focusing in particular on the optimal way to schedule RT.

RESULTS

Description of selected studies and quality assessment

A total of 787 articles were identified, of which 33 articles qualified for inclusion. The flow diagram for study selection is shown in Figure 1. The characteristics of the included studies are summarized in Tables 1 and 2. Although methods for managing missing data are not adequately described in some studies, none of the included studies had a NOS < 6, which suggests all were of high quality.
Figure 1

Flow diagram of studies identification and selection

Table 1

Baseline characteristics of the included studies

StudyPatients No.Age(year)StudyperiodCountryFollow upGender(Male/Female)DesignQuality scoreHistology*Nodal stage (NX-1/N2-3)Nodal level (I-II/III-IV)
1973Jesse184NA1948–1968USA> 3YNAR71,363/121162/48
1975Fried43NA1958–1969USANA2:1R61,2,3NANA
1979Nordstrom3960(13–88)1960–1973USANA40/11R61,2,38/43NA
1981Leipzig3251(22–76)1969–1977USANA2:1R7114/18NA
1986Carlson93NA1968–1980USA> 3Y70/23R71,2,341/5261/32
1987Bataini13857.5(15–82)1960–1980USA> 5Y117/21R8145/93NA
1990Glynne5861(12–85)1954–1986UK35(4–300)M53/34R71,311/76NA
1990Harper6958.5(26–91)1964–1986Australia> 2Y58/11R8118/51NA
1990Marcial7258.5(24–85)1965–1987USANA50/22R61,312/6035/37
1995Weir14460(28–90)1970–1986Canada3.5(4–15)Y110/34R81,2,379/65NA
1997Reddy5259(30–79)1974–1989USA> 5Y50/2R919/43NA
1997 Sinnathamby6762(29–84)1983–1992Australia7M-7Y51/18R81,39/60NA
1997van der4466(20–86)1974–1991Netherlands7.3Y(2–18.8)35/9R71,2,34/40NA
1998Colletier13659(25–83)1968–1992Canada58(3–267)M103/33R7141/95104/32
1998Strojan5656(33–81)1975–1994Slovenia8.6(1.6–17.8)Y50/6R816/5039/17
2000Grau35262(18–92)1975–1995Denmark5Y248/104R71,348/225277/0
2000McMahon3467(45–84)1987–1998Australia2.7(0.9–6.7)Y28/10R816/3231/7
2002Tong4557(29–91)1988–1998Hong Kong79M(27–110)37/8R71,2,37/3820/25
2002Yalin11448(18–78)1976–1988ChinaNANAR71,2,333/81NA
2002Zuur1462.6(34.7–82.8)1975–1999Netherlands2–67M8/8R71,22/133/12
2006Boscolo7964.7±9.31980–2001Italy15Y69/13R8110/6260/12
2007Aslani6157(37–87)1987–2002Canada31(7–168)M49/12R71,316/4553/8
2007Beldi11359.3(23–88)1980–2004ItalyNA93/20R71,2,321/9283/30
2008Huang3163.3(36–84)1980–2000TaiwanNA35/13R813/4539/9
2009Ligey9559(38–80)1990–2007France3.3Y(5M-11.7Y)84/11R71,325/7077/18
2009Lu6053(23–81)1989–2003China58(10–135)M46/14R8110/5044/16
2009Rodel5855(37–77)1980–2004Germany83.5M(24–162)58/10R71,2,39/4955/3
2011Chen6060(42–90)2001–2009USA30M(3–90)39/21R815/5551/9
2011Wallace17961(26–89)1990–2006USA4.2Y(0.2–25.4)157/22R8118/161NA
2012Fakhrian6560(39–90)1988–2009Germany64(3–219)M52/13R91,314/5146/19
2012Perkins4660(40–82)1989–2008USA4.6Y(7M-18Y)NAR913/43NA
2014Demiroz4153(38-72)1994-2009USA11-126M37/4R914/3733/8
2015Straetmans46NA1997-2010Netherlands, GermanyNA44/7R814/42NA

According to UICC/AJCC staging system. R = retrospective; Y = year; M = month; NA = Not available;

1 = squamous cell carcinoma; 2 = adenocarcinoma; 3 = undifferentiated carcinoma

Table 2

Baseline characteristics of the treatments of the included studies

StudyPatients No.ChemotherapyRadiotherapySurgery
Patients No.Patients No.Treatment volumePatients No.Types of surgery
1973Jesse184080BN+PPTS,IN+PPTS,BN,IN132ND,E
1975Fried43043BN+PPTS,IN+PPTS,BN,IN16ND
1979Nordstrom39039BN+PPTS,IN+PPTS,IN34ND
1981Leipzig32024BN+PPTS,IN+PPTS,BN,IN24ND
1986Carlson93093BN+PPTS,IN+PPTS,BN,IN70ND,E
1987Bataini1380138BN+PPTS,BN,IN48ND
1990Glynne58158BN+PPTS,IN+PPTS,BN,IN6ND
1990Harper69069BN+PPTS,IN+PPTS,BN,IN30ND
1990Marcial72072BN+PPTS,IN+PPTS,BN,IN31ND,E
1995Weir1440144BN+PPTS,IN+PPTS,BN,IN71E
1997Reddy52052BN+PPTS,IN39ND,E
1997Sinnathamby67063BN,IN44ND,E
1997van der44044BN+PPTS,IN+PPTS,BN,IN31ND,E
1998Colletier1360136BN+PPTS,IN+PPTS,BN,IN136ND,E
1998Strojan56056BN+PPTS,IN+PPTS,IN56ND,E
2000Grau3520250BN+PPTS,IN169ND,E
2000McMahon34034BN+PPTS,IN34ND
2002Tong45836BN+PPTS13ND,E
2002Yalin1143976BN+PPTS,IN+PPTS,BN,IN24ND,E,T
2002Zuur14014BN+PPTS,IN+PPTS,BN,IN7ND
2006Boscolo79079BN+PPTS,IN50ND
2007Aslani61061BN+PPTS,BN,IN29ND,E
2007Beldi11321113BN+PPTS,BN,IN99ND,E
2008Huang311631BN+PPTS30ND
2009Ligey954395BN+PPTS,IN+PPTS,BN,IN79ND
2009Lu601460BN+PPTS,BN,IN9E
2009Rodel582250BN+PPTS,IN53ND
2011Chen603260BN+PPTS,IN+PPTS,IN45ND,E
2011Wallace17913179BN+PPTS,IN+PPTS,IN109ND
2012Fakhrian651965BN+PPTS,IN51ND,E
2012Perkins461446BN+PPTS,IN+PPTS,BN,IN40ND,E
2014Demiroz412541BN+PPTS,BN,IN22ND
2015Straetmans51848BN+PPTS,BN,IN51ND

Abbreviations: BN = Bilateral neck; IN = Ipsilateral neck; PPTS = Potential primary tumor sites.

Neck dissection = ND, Excision = E, Thyroidectomy = T.

According to UICC/AJCC staging system. R = retrospective; Y = year; M = month; NA = Not available; 1 = squamous cell carcinoma; 2 = adenocarcinoma; 3 = undifferentiated carcinoma Abbreviations: BN = Bilateral neck; IN = Ipsilateral neck; PPTS = Potential primary tumor sites. Neck dissection = ND, Excision = E, Thyroidectomy = T.

RT alone versus RT combined with surgery

Eighteen studies [2, 5, 9, 10, 16–29], with a total of 1582 patients, were included in this analysis. Compared to RT alone, the combination of RT and surgery significantly improved 5-year OS (RR = 0.66, 95% CI 0.52–0.83, p = 0.0004) (Figure 2A). The benefit to 5-year DFS showed a similar trend (RR = 0.81, 95% CI 0.62–1.07, p = 0.13) (Figure 2B), though this did not reach statistical significance. Additionally, surgery in combination with RT was associated with a significantly decreased NR rate (RR = 0.74, 95% CI 0.59–0.72, p = 0.008) (Figure 2D) and an increased CR rate (RR = 0.37, 95% CI 0.21–0.64, p = 0.0003) (Figure 2C).
Figure 2

Meta-analysis of (A) 5-year OS, (B) 5-year DFS,(C) CR, (D) NR between RT alone and RT combined with surgery. S, Surgery; RT, Radiotherapy.

Meta-analysis of (A) 5-year OS, (B) 5-year DFS,(C) CR, (D) NR between RT alone and RT combined with surgery. S, Surgery; RT, Radiotherapy.

Ipsilateral versus bilateral neck irradiation

Sixteen studies [1, 3–7, 11–15, 23, 20–33] with a total of 1449 patients, meeting the inclusion criteria were selected for this analysis (Table B). Bilateral neck irradiation contributed to better local control with a lower NR rate (RR = 0.61, 95% CI 0.41–0.91, p = 0.01) (Figure 3A) and PTE rate (RR = 0.44, 95% CI 0.26–0.77, p = 0.004) (Figure 3B). This was especially true for contralateral neck control (RR = 0.30, 95% CI 0.15–0.59, p < 0.0005) (Figure 3C). Moreover, when compared to ipsilateral irradiation, bilateral neck irradiation showed a potential survival advantage with greater 5-year OS (RR = 0.86, 95% CI 0.61–1.22, p = 0.40) (Figure 3D) and 5-year DFS (RR = 0.81, 95% CI 0.64–1.03, p = 0.09) (Figure 3E), although this benefit was not statistically significant.
Figure 3

Meta-analysis of (A) NR, (B) PTE, (C) CNR, (D) 5-year OS, and (E) 5-year DFS between ipsilateral neck irradiation and bilateral neck irradiation. BN, Bilateral neck; IN, Ipsilateral neck; RT, Radiotherapy.

Meta-analysis of (A) NR, (B) PTE, (C) CNR, (D) 5-year OS, and (E) 5-year DFS between ipsilateral neck irradiation and bilateral neck irradiation. BN, Bilateral neck; IN, Ipsilateral neck; RT, Radiotherapy.

Neck-only versus neck plus PPTS irradiation

Fifteen studies [1–8, 11–13, 15, 22, 30, 33], with a total of 1347 patients, fulfilled the inclusion criteria and were included in this analysis. As compared to neck-only irradiation, superior 5-year DFS (RR 0.75, 95% CI 0.61–0.92, p = 0.005) (Figure 4A) and a trend toward increased 5-year OS (RR = 0.70, 95% CI 0.48–1.01, p = 0.06) (Figure 4B) were observed in patients treated with neck and PPTS irradiation. In addition, neck and PPTS irradiation had a significant advantage for reducing NR rate (RR = 0.72, 95% CI 0.56–0.92, p = 0.009) (Figure 4C), CNR rate (RR = 0.23, 95% CI 0.12–0.45, p < 0.0001) (Figure 4D) and PTE rate (RR = 0.59, 95% CI 0.39–0.89, p = 0.01) (Figure 4E).
Figure 4

Meta-analysis of (A) NR, (B) PTE, (C) CNR, (D) 5-year OS, and (E) 5-year DFS between neck only irradiation and neck plus potential primary tumour sites irradiation. N, Neck only; N+PPTS, Neck plus potential primary mucosa sites; RT, Radiotherapy.

Meta-analysis of (A) NR, (B) PTE, (C) CNR, (D) 5-year OS, and (E) 5-year DFS between neck only irradiation and neck plus potential primary tumour sites irradiation. N, Neck only; N+PPTS, Neck plus potential primary mucosa sites; RT, Radiotherapy.

Toxic effects of different radiotherapeutic regimens

Only two of the included studies [11, 15] compared toxicities between ipsilateral neck irradiation and bilateral neck plus PPTS irradiation, and the toxicity data could only be assessed for severe acute toxicity and xerostomia. We found there was an increased risk of severe acute toxicity (RR = 1.91, 95% CI 1.26–2.88, p = 0.002) (Supplementary Figure S1A) and xerostomia (RR = 6.82, 95% CI 0.96–48.55, p = 0.06) (Supplementary Figure S1B) in the group with bilateral neck and PPTS irradiation.

DISCUSSION

Optimal treatment for patients with NCUP remains uncertain. The incidence of NCUP is about 3 cases per 1,000,000 per year. Its rarity makes randomized and prospective studies unavailable, and leaves clinicians with only small retrospective studies for clinical decision making. To the best of our knowledge, this study is the first meta-analysis with a focus on comparing the therapeutic efficacies of different treatment regimens, and on providing a higher level of evidence for optimizing the RT schedule in NCUP. Some studies held that surgery plus RT resulted in a higher probability of cure [2, 5, 9, 27, 28], while others reported that the outcome of surgery plus RT were similar to those of definitive RT alone, but with a higher risk of severe complications [19, 25, 29]. We therefore first performed a comparison of RT alone with RT plus surgery. The pooled analysis demonstrated that RT plus surgery was associated with a greater 5-year OS rate than RT alone. Moreover, there was a beneficial trend toward a higher 5-year DFS, though the effect was not significant. The higher CR rate and lower NR rate is also consistent with a survival benefit from the combination of surgery and RT. For neck-irradiation settings, the current guidelines suggest treating the involved lymph node field [34]. However, some reports indicate that patients administered RT to the bilateral neck nodes appeared to have greater local control and higher survival rates than those who received only ipsilateral irradiation [1, 4, 6, 15]. In the present pooled analysis, significantly less contralateral cervical recurrence or emergence of a primary tumor was noted in patients receiving bilateral irradiation, and there was trend toward increased 5-year OS and DFS. These findings suggest that current guidelines recommending the involved lymph node field as the standard RT schedule may need to be re-evaluated for the NCUP setting. As to the value of irradiation of the PPTS, although current guidelines recommend it as routine consideration for inclusion in the target volume [34], conclusions drawn from currently available evidence are controversial. Some studies have shown a higher 5-year OS rate and better regional control with addition of irradiation of potential head and neck mucosal sites of cancer growth [1, 4–6, 8, 13, 15], whereas, other trials observed that mucosal irradiation reduced both the emergence of primary tumors and regional recurrence, but did not affect OS [3, 7, 12]. In the pooled analysis of all these trials, not only was an advantage for regional control validated, so was a survival benefit in patients treated with irradiation of the neck and PPTS. We also evaluated the toxic effects of different RT regimens. Because the data were limited, we only assessed severe acute toxicities and xerostomia. We found a significantly higher risk of these adverse events in the RT to the bilateral neck plus PPTS group. However, it is believed that these severe acute toxicities are clinically manageable, and xerostomia could be minimized by application of intensity modulated RT (IMRT) [11, 15]. There were several limitations to this study. First, all the included studies were retrospective and the sample groups were small. There was not sufficient data to perform subgroup analyses based on lymph node levels, lymph node stages, histological types, sequence of surgery and RT, or radiation dosage. Second, these studies were performed over a long time-span. Consequently, the techniques for delivering RT were varied, and precision RT techniques, such as 3-D conformal RT and IMRT, were not yet broadly applied. This could result in an underestimation of the actuarial effect of RT. To address these issues, future multicenter RCTs are needed.

MATERIALS AND METHODS

Literature search and selection

Two authors (X.M.L. and X.X.Z.) independently carried out systematic literature searches of EMBASE, Cochrane, Pubmed and Web of Science before September 25, 2015. The following terms were used: occult primary, unknown primary, neck lymph node, cervical lymph node, metastatic, metastases, cancer, neoplasm, tumor, carcinoma, radiotherapy, irradiation, radiation. Studies meeting the following selection criteria were included. (1) Study population: patients with cervical lymph node metastases from unknown primary sites, and with no cancer history. (2) Study design: comparative studies comparing RT alone with a combination of RT and surgery (radical neck dissection, selective neck dissection, or excisional biopsy); comparing ipsilateral irradiation with bilateral irradiation; or comparing neck-only irradiation with neck and potential primary tumor site (PPTS) (nasopharynx, oropharynx, larynx, and/or hypopharynx) irradiation. (3) Language: English. (4) Studies with available data on at least one of the pre-specified endpoints: 5-year OS, 5-year disease free survival (DFS), neck recurrence (NR), complete response (CR), primary tumor emergence (PTE), ipsilateral neck recurrence (INR), contralateral neck recurrence (CNR), severe acute toxicity (RTOG grade≥3) and xerostomia. Editorials, letters to the editor, and review articles were excluded (Figure 1).

Data extraction

The following items were extracted independently by the two authors (X.M.L. and D.H.L.) from the published articles: year of publication, first author, country, study period, demographic and clinical information on the study patients (age, gender, histology, N stage, N level), schedule of treatment, number of patients, outcome results, and follow-up. Any disagreement was resolved through further discussion and including a third author.

Quality assessment

The quality of each study was assessed using the Newcastle-Ottawa Quality Assessment Scale (NOS), which considers of the following factors: patient selection, comparability of the study groups, and assessment of outcome [35, 36]. Each study was assigned a score of between 0 and 9. Any discrepancies were resolved by discussion. Studies with a score of > 5 were regarded as high-quality studies.

Statistical analysis

All the meta-analyses were performed using Review Manager 5.2 (Cochrane Collaboration, Oxford, UK). Each pre-specified outcome was measured in terms of the risk ratios (RRs) [36] and its 95% confidence intervals (CIs). Two-sided values of P < 0.05 were considered statistically significant. Heterogeneity among studies was determined by the Chi-square test and an inconsistency (I2) statistic of forest plots. I2 > 40% or P < 0.10 indicated significant heterogeneity [37]. If there was significant heterogeneity among studies, a random-effects model was used. Otherwise, a fixed-effects model was used [37, 38].

CONCLUSIONS

This study suggests that, in patients with NCUP, surgery combined with RT to bilateral neck and PPTS may be the preferable treatment option, as it is associated with improvements in survival and regional control. On the other hand, this recommendation is not based on randomized trials, and one must be alert for severe acute toxicity and xerostomia.
  35 in total

1.  Radiotherapeutic management of cervical lymph node metastases from an unknown primary site.

Authors:  Stephanie M Perkins; Christopher R Spencer; Rebecca D Chernock; Bruce H Haughey; Brian Nussenbaum; Douglas R Adkins; David I Kuperman; Wade L Thorstad
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2012-07

2.  Radiation treatment of cervical lymph node metastases from an unknown primary: an analysis of outcome by treatment volume and other prognostic factors.

Authors:  L Weir; T Keane; B Cummings; P Goodman; B O'Sullivan; D Payne; P Warde
Journal:  Radiother Oncol       Date:  1995-06       Impact factor: 6.280

3.  Cervical lymph node metastases from an unknown primary.

Authors:  D G Nordstrom; H H Tewfik; H B Latourette
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-01       Impact factor: 7.038

4.  Cervical nodal metastases from occult primary: undifferentiated carcinoma versus squamous cell carcinoma.

Authors:  Chi-Chung Tong; Mai-Yee Luk; Sin-Ming Chow; Kai-Cheong Ngan; Wai-Hon Lau
Journal:  Head Neck       Date:  2002-04       Impact factor: 3.147

5.  Treatment of cervical lymph node metastasis from an unknown primary tumor, with a review of the literature.

Authors:  H J van der Planken; R M Tiwari; A B Karim
Journal:  Strahlenther Onkol       Date:  1997-03       Impact factor: 3.621

6.  Role of radiotherapy in the treatment of cervical lymph node metastases from an unknown primary site: retrospective analysis of 113 patients.

Authors:  Debora Beldì; Barbara A Jereczek-Fossa; Alberto D'Onofrio; Giuseppina Gambaro; Maria Rosaria Fiore; Francesco Pia; Fausto Chiesa; Roberto Orecchia; Marco Krengli
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-08-22       Impact factor: 7.038

7.  The occult head and neck primary: to treat or not to treat?

Authors:  K Sinnathamby; L J Peters; C Laidlaw; P G Hughes
Journal:  Clin Oncol (R Coll Radiol)       Date:  1997       Impact factor: 4.126

8.  Metastatic carcinoma in the cervical lymph nodes from an occult primary: a conservative approach to the role of radiotherapy.

Authors:  R G Glynne-Jones; A K Anand; T E Young; R J Berry
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-02       Impact factor: 7.038

9.  Cervical nodal metastases of unknown origin.

Authors:  B Leipzig; M L Winter; J A Hokanson
Journal:  Laryngoscope       Date:  1981-04       Impact factor: 3.325

Review 10.  Benefits and Harms of Breast Cancer Screening: A Systematic Review.

Authors:  Evan R Myers; Patricia Moorman; Jennifer M Gierisch; Laura J Havrilesky; Lars J Grimm; Sujata Ghate; Brittany Davidson; Ranee Chatterjee Mongtomery; Matthew J Crowley; Douglas C McCrory; Amy Kendrick; Gillian D Sanders
Journal:  JAMA       Date:  2015-10-20       Impact factor: 56.272

View more
  8 in total

1.  Tumor control of cervical lymph node metastases of unknown primary origin: the impact of the radiotherapy target volume.

Authors:  Jos M J A A Straetmans; Marijn Stuut; Sanne Wagemakers; Frank Hoebers; Johannes H A M Kaanders; Ernst Jan M Speel; Willem J G Melchers; Piet Slootweg; Bernd Kremer; Martin Lacko; Robert P Takes
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-02-25       Impact factor: 2.503

2.  Inter-observer variability of clinical target volume delineation in definitive radiotherapy of neck lymph node metastases from unknown primary. A cooperative study of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Head and Neck Group.

Authors:  Marianna Trignani; Angela Argenone; Saide Di Biase; Daniela Musio; Anna Merlotti; Stefano Ursino; Ester Orlandi; Domenico Genovesi; Almalina Bacigalupo
Journal:  Radiol Med       Date:  2019-03-09       Impact factor: 3.469

3.  Long-term results of radio(chemo)therapy in metastatic carcinoma to cervical lymph nodes from an unknown primary. Adult Comorbidity Evaluation 27 score as a predictor of survival.

Authors:  Miloslav Pala; Pavla Novakova; Zdena Pechacova; Lucie Vesela; Antonin Vrana; Jarmila Sukova; Petra Holeckova; Tereza Drbohlavova; Tomas Podlesak; Lubos Petruzelka
Journal:  Strahlenther Onkol       Date:  2022-08-09       Impact factor: 4.033

4.  Patterns of care analysis for head & neck cancer of unknown primary site: a survey inside the German society of radiation oncology (DEGRO).

Authors:  Jens Müller von der Grün; Dimitra Bon; Claus Rödel; Panagiotis Balermpas
Journal:  Strahlenther Onkol       Date:  2018-05-14       Impact factor: 3.621

Review 5.  Diagnostic and treatment modalities for patients with cervical lymph node metastases of unknown primary site - current status and challenges.

Authors:  Jens Müller von der Grün; Aykut Tahtali; Shahram Ghanaati; Claus Rödel; Panagiotis Balermpas
Journal:  Radiat Oncol       Date:  2017-05-10       Impact factor: 3.481

6.  Evaluation of radiation treatment volumes for unknown primaries of the head and neck in the era of FDG PET.

Authors:  Alexis Platek; Michael Mix; Varun Chowdhry; Mark Farrugia; Michael A Lacombe; Jeffrey A Bogart; Luke Degraaf; Austin Iovoli; Hassan Arshad; Kimberly Wooten; Vishal Gupta; Wesley L Hicks; Mary E Platek; Seung S Hahn; Anurag K Singh
Journal:  PLoS One       Date:  2020-04-10       Impact factor: 3.240

7.  Long-term results of elective mucosal irradiation for head and neck cancer of unknown primary in Chinese population: The EMICUP study.

Authors:  Shengjin Dou; Rongrong Li; Lin Zhang; Zhuoying Wang; Li Xie; Chenping Zhang; Guopei Zhu
Journal:  Cancer Med       Date:  2020-01-17       Impact factor: 4.452

8.  Radiotherapeutic management of cervical lymph node metastases from an unknown primary site - experiences from a large cohort treated with modern radiation techniques.

Authors:  Tanja Sprave; Alexander Rühle; Katharina Hees; Tobias Kalckreuth; Vivek Verma; Raluca Stoian; Constantinos Zamboglou; Jens Pfeiffer; Roland Laszig; Andreas Knopf; Anca-Ligia Grosu; Nils H Nicolay
Journal:  Radiat Oncol       Date:  2020-04-15       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.